生物谷報道：日前，第四軍醫(yī)大學(xué)西京醫(yī)院普三科的研究人員在研究中發(fā)現(xiàn),，肝癌的發(fā)生與抑癌基因PTEN低表達有關(guān),，為今后進一步對PTEN在人肝癌細胞中的研究奠定了基礎(chǔ)。
PTEN基因是定位于人體第10q23染色體上的腫瘤抑制基因,。為了探討PTEN表達與肝癌發(fā)生,、發(fā)展的關(guān)系，西京醫(yī)院普三科的研究人員應(yīng)用免疫組織化學(xué)技術(shù)，檢測PTEN蛋白在63例肝癌組織,、14例肝硬化組織和8例正常肝組織中的表達情況,，以觀察該基因與肝癌轉(zhuǎn)移和預(yù)后的關(guān)系。
研究發(fā)現(xiàn),，肝癌中PTEN表達陰性率為30.16％（19/63）,，顯著高于正常肝組織0（0/8）和肝硬化組織7.15％（1/14）。隨著惡性程度的增高,，PTEN表達陰性率隨之增加,。PTEN表達陰性與是否轉(zhuǎn)移及預(yù)后顯著相關(guān)。結(jié)果表明,，抑癌基因PTEN低表達多見于肝癌進展期,，并與肝癌是否轉(zhuǎn)移以及臨床預(yù)后相關(guān)。
最新國外也有研究表明,，SMAD4和PTEN兩個基因在肝癌的起始中起決定性作用,。剛剛出版的著名臨床雜志JCI報道了這一信息,。這一研究與中國國內(nèi)的研究基本相似,，這一研究為將來預(yù)防和治療肝癌提供重要的理論依據(jù)。英文的信息如下：
Cholangiocellular carcinoma (CC) is the second most common type of primary liver cancer and is associated with a poor prognosis. It has been previously demonstrated that CCs possess alterations of a number of tumor-suppressor genes and oncogenes, however the key events that induce tumor formation have remained unclear. In a study appearing online in June in advance of print publication in the July issue of the Journal of Clinical Investigation, Chu-Xia Deng and colleagues from the NIH, generated a line of mice that develop CC by specifically disrupting expression of the tumor suppressor genes SMAD4 and PTEN in the livers of these mice. Tumors formed in the bile ducts of these animals by 4-7 months of age. The authors show that SMAD4 and PTEN regulate each others' activity in order to balance their expression and repress CC formation. The authors also examined human CC specimens and found that PTEN was inactivated in the majority of cases, and SMAD4 expression was lost in about half of the tumors examined. The results of this study help us understand the relationship between SMAD4 and PTEN and extend our understanding of CC formation.
TITLE: Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten mice
AUTHOR CONTACT:
Chu-Xia Deng
National Institutes of Health, Bethesda, Maryland, USA.
View the PDF of this article at: http://https://www.the-jci.org/article.php?id=27282
Contact: Brooke Grindlinger
Journal of Clinical Investigation
